Quantcast

Latest Organofluorides Stories

2014-06-10 23:16:02

Avail is conducting a phase 1, open-label pharmacokinetic and pharmacodynamic study of a single dose of an experimental drug in subjects with hepatic impairment and in matched healthy volunteers. DeLand, FL (PRWEB) June 10, 2014 To see if you qualify for this Hepatic Impairment Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required, and you may...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...

2014-06-09 23:09:13

The law firm Schlichter, Bogard & Denton, LLP reports that it is investigating claims alleging that the atypical antipsychotic drug, Risperdal, is linked to serious injuries to boys and men. St. Louis, Missouri (PRWEB) June 09, 2014 A May 2014 report in Scientific American, titled Widely Used Autism Drug Carries Heavy Risks for Children, detailed the many side-effects caused by Risperdal, a prescription atypical antipsychotic drug. As stated in Scientific American, Risperdal can...

2014-06-09 23:01:31

The Firm is investigating Risperdal lawsuits on behalf of men and boys who allegedly developed gynecomastia due to their use of Risperdal. New York, New York (PRWEB) June 09, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a new report out of Australia has detailed a steep rise in the use of antipsychotic drugs among that country’s children. The report, which was prepared by the Drug Utilisation Sub...

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-06-04 23:03:29

The Firm is representing numerous clients in Risperdal lawsuits, all of whom allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) June 04, 2014 Plaintiffs in Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic have asked a Pennsylvania state court judge to reinstate their punitive damage...

2014-06-03 11:22:42

University of Colorado Denver A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma...

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-06-02 22:55:01

University of Colorado Denver A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related